All News

Approximately 10.5 million US adults, or 5% of the population, have the atrial fibrillation, according to new prevalence estimates.

The term "flare" is used consistently in discussions of AD, but is everyone talking about the same thing? New research closes in on a patient-centered definition.

Which state retains the most medical residents? Or has the lowest cancer rate? Answers and more insights from a nationwide analysis, here.

The GSK reformulation induced acceptable immune responses for both influenza A and B strains, overcoming a setback earlier in the ability to successfully neutralize the latter.

Your daily dose of the clinical news you may have missed.

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.

The needle-free nasal spray, if approved, would be the first new administration method for epinephrine in young children in 35 years.

Regulations have been amended under the Mammography Quality Standards Act of 1992 to ensure women receive quality mammography for early breast cancer detection and prevention.

The cortisol deficiency central to congenital adrenal hyperplasia requires lifelong treatment with distinct shifts in management required at each developmental stage.

In a study of persons with moderate-to-severe atopic dermatitis, lebrikizumab monotherapy for 16 weeks resulted in improved quality of life and mental health.

The new data amend that from prelicensure trials, which did not include fair representation of older adults and others more vulnerable to severe RSV disease.

Your daily dose of the clinical news you may have missed.

Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.

In a study of patients with atopic dermatitis, tralokinumab was effective and safe in elderly patients and those with severe comorbidities.

The Bridge Access Program allowed Americans who are uninsured or underinsured to receive COVID-19 vaccination at not cost and was ended abruptly last month.

Your daily dose of the clinical news you may have missed.

Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.

In a large study of patients with COPD, a small increase in 5-year all-cause mortality risk was observed among those using roflumilast.